8-K: Rafael Holdings and Cyclo Therapeutics Announce Definitive Merger Agreement

Rafael Holdings and Cyclo Therapeutics have agreed to merge, focusing on the development of Trappsol Cyclo for Niemann-Pick Disease Type C1.

Summary

• Rafael Holdings and Cyclo Therapeutics have entered into a definitive merger agreement.
• Rafael Holdings will issue Class B common stock to Cyclo Therapeutics shareholders based on an exchange ratio valuing Cyclo shares at $0.95 per share.
• The valuation of Rafael Holdings is based on its cash value combined with the value of its marketable securities and certain other investments, less certain current liabilities.
• The cash value will also take into account the funding of Cyclo's operations by Rafael through convertible notes until closing.
• Following the merger, Rafael Holdings intends to fund Cyclo's TransportNPC clinical trial to its 48-week interim analysis.
• The merger is expected to close in late 2024, pending shareholder approvals, SEC effectiveness of a registration statement, and other customary closing conditions.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook on the merger, highlighting the potential of Trappsol Cyclo and the commitment to funding the clinical trial. The language is optimistic and forward-looking, suggesting a positive sentiment from an investment perspective.

Positives

• The merger will combine resources to focus on the development of Trappsol Cyclo.
• Rafael Holdings is committed to the program and will leverage its resources to help bring this much needed treatment option to NPC patients.
• Cyclo Therapeutics has made substantial progress in advancing its lead asset, Trappsol Cyclo.
• The TransportNPC Phase 3 clinical study for Niemann-Pick Disease Type C1 is fully enrolled.
• The merger is expected to solidify Cyclo's commitment to deliver results for shareholders and patients.

Risks

• The merger is subject to shareholder approvals, SEC effectiveness of a registration statement, and other customary closing conditions.
• There is no guarantee that the proposed business combination will be completed in the anticipated timeframe or at all.
• The success of the TransportNPC clinical trial is not guaranteed, and results may not be favorable.
• The companies face risks related to the development, regulatory approval, and commercialization of their product candidates.

Future Outlook

Rafael Holdings intends to focus its efforts on making Trappsol Cyclo its lead clinical program after the merger, with results from the 48-week interim analysis of the TransportNPC trial expected in the middle of 2025.

Management Comments

• Bill Conkling, President and CEO of Rafael Holdings, stated that the merger is a major step forward in their strategy to invest in, develop, and commercialize clinical stage assets.
• N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, believes that the strength of Rafael's balance sheet and management team will solidify their commitment to deliver results for shareholders and patients.

Industry Context

This merger reflects a trend of consolidation in the biotechnology sector, where companies combine resources to advance promising clinical programs, particularly in areas of high unmet medical need like rare diseases.

Comparison to Industry Standards

• The merger between Rafael Holdings and Cyclo Therapeutics is similar to other strategic acquisitions in the biotech industry where larger companies acquire smaller firms with promising clinical assets.
• The focus on a Phase 3 clinical trial for a rare disease is consistent with industry trends where companies are targeting niche markets with high unmet medical needs.
• The funding commitment to the TransportNPC trial is comparable to other investments in late-stage clinical programs.
• The valuation of Cyclo Therapeutics at $0.95 per share is a specific metric that would need to be compared to other similar transactions to assess its fairness.

Management Changes

Stakeholder Impact

• Shareholders of Cyclo Therapeutics will receive shares of Rafael Holdings Class B common stock.
• Patients with Niemann-Pick Disease Type C1 may benefit from the continued development of Trappsol Cyclo.
• Employees of both companies may experience changes as a result of the merger.

Next Steps

• Shareholder approvals from both Rafael Holdings and Cyclo Therapeutics are required.
• A registration statement for the shares of Rafael Holdings Class B common stock to be issued in the transaction must be declared effective by the SEC.
• The companies will work to satisfy other customary closing conditions.
• Rafael Holdings will fund the TransportNPC clinical trial to its 48-week interim analysis.
• The 48-week interim analysis results from the TransportNPC trial are expected in the middle of 2025.

Key Dates

Keywords

merger, Rafael Holdings, Cyclo Therapeutics, Trappsol Cyclo, Niemann-Pick Disease Type C1, TransportNPC, clinical trial, biotechnology, pharmaceutical, rare disease